Oramed Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Oramed Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Oramed Pharmaceuticals Inc Strategy Report
- Understand Oramed Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Oramed Pharmaceuticals Inc (Oramed) is a pre-clinical pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and is administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
1185 Avenue Of The Americas, 3rd Floor, New York, 10036
Website
oramed.com
Telephone
1 646 8441164
No of Employees
15
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ORMP (NASD)
Revenue (2022)
$1.3M
-50.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
115.1%
(2022 vs 2021)
Market Cap*
$93.2M
Net Profit Margin (2022)
XYZ
130.5%
(2022 vs 2021)
* As of and is in US$
Oramed Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| ORMD 0801 (Oral Insulin Capsule): |
| Type 1 Diabetes |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company and Hefei Tianhui Biotech entered into an agreement to form a joint venture to advance oral drug products. |
| 2023 | Patent Grant | In January, the company was awarded U.S. combination therapy patent for GLP-1 and insulin for the treatment of diabetes. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement with Medicox Co to distribute oral insulin candidate (ORMD-0801) for ten years in the Republic of Korea. |
Competitor Comparison
| Key Parameters | Oramed Pharmaceuticals Inc | AbbVie Inc | Novo Nordisk AS | Biocon Ltd | Halozyme Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Denmark | India | United States of America |
| City | New York | North Chicago | Bagsvaerd | Bangalore | San Diego |
| State/Province | New York | Illinois | - | Karnataka | California |
| No. of Employees | 15 | 50,000 | 63,370 | 3,408 | 373 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kevin Rakin | Chairman | Executive Board | 2016 | 61 |
| Nadav Kidron | Chief Executive Officer; Director; President | Executive Board | 2006 | 48 |
| Miriam Kidron, Ph.D. | Chief Scientific Officer; Director | Executive Board | 2006 | 82 |
| David Silberman | Chief Financial Officer; Treasurer | Senior Management | 2021 | 39 |
| Netanel Derovan | Secretary; Chief Legal Officer | Senior Management | 2022 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer